Severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) is the pathogen that causes
coronavirus disease 2019 (COVID-19). As of 25 May 2020, the outbreak of COVID-19 has …

The rapid spread of coronavirus disease 2019 (COVID-19), caused by severe acute
respiratory syndrome–coronavirus 2 (SARS-CoV-2), has resulted in an unprecedented …

Background No therapy is approved for COVID-19 pneumonia. The aim of this study was to
assess the role of tocilizumab in reducing the risk of invasive mechanical ventilation and …

Objective The coronavirus disease 2019 (COVID‐19) has rapidly developed into a
pandemic. Increased levels of ferritin due to cytokine storm and secondary hemophagocytic …

Importance The coronavirus disease 2019 (COVID-19) pandemic is threatening billions of
people worldwide. Tocilizumab has shown promising results in retrospective studies in …

The outbreak of coronavirus disease 2019 (COVID-19), caused by Severe Acute Respiratory
Syndrome Coronavirus 2 (SARS-CoV-2) infection, has emerged in China in December 2019 …

In severe SARS-CoV-2 infections, emerging data including recent histopathological studies
have emphasized the crucial role of endothelial cells (ECs) in vascular dysfunction …

Importance Therapies that improve survival in critically ill patients with coronavirus disease
2019 (COVID-19) are needed. Tocilizumab, a monoclonal antibody against the interleukin 6 …

Background Severe coronavirus disease 2019 (COVID-19) can manifest in rapid
decompensation and respiratory failure with elevated inflammatory markers, consistent with …

Background Tocilizumab (TCZ), a humanized monoclonal antibody targeting the interleukin-
6 (IL-6) receptor, has been proposed for the treatment of COVID-19 patients; however …